TALVEY is administered under the skin as a subcutaneous injection and is injected by a qualified healthcare professional.
The drug TALVEY is administered in the abdomen, thigh or other approved locations subcutaneously and is dispensed exclusively through the TECVAYLI and TALVEY Risk Evaluation and Mitigation Strategy (REMS) program to manage risks like Cytokine Release Syndrome (CRS) and neurologic toxicity.
Treatment with TALVEY also begins with a step-up dosing schedule to mitigate CRS risks, followed by a maintenance phase:
Weekly Schedule of TALVEY (0.4 mg/kg): Involves step-up doses on Day 1 (0.01 mg/kg) and Day 4 (0.06 mg/kg), with the first full treatment dose on Day 7.
Biweekly Schedule of TALVEY (0.8 mg/kg): Includes three step-up doses on Days 1, 4, and 7, followed by the first treatment dose on Day 10.
Pretreatment and Hospitalization involved with TALVEY.
Pretreatment: Patients are given medications—such as corticosteroids, antihistamines, and antipyretics—prior to step-up doses to prevent severe reactions.
Hospitalization: Mandatory 48-hour hospitalization is required for TALVEY following each step-up dose to monitor for CRS and neurological events.
The indications for TALVEY are for treatment of adults with relapsed or refractory multiple myeloma (RRMM), who have also received at least 4 prior lines of therapy, which include, a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.
TALVEYS indications were granted accelerated approval by the U.S. FDA based on overall response rate and durability of response. Continued approval may depend on verification in confirmatory clinical trials.
TALVEY is a first-in-class bispecific T-cell engager that targets GPRC5D on multiple myeloma cells and CD3 on T cells.
Treatment carries boxed warnings for cytokine release syndrome (CRS) and neurologic toxicity (including ICANS), and is distributed through a restricted Risk Evaluation and Mitigation Strategy (REMS) program.
The possible skin side effects of TALVEY are rashes and skin reactions, dry skin (Xerosis), Palmoplantar Peeling/ Skin Scaling, Nail Changes and even infection site reactions.
Rashes and Skin Reaction side effects of TALVEY include general rashes, maculo-papular rashes (small, flat red spots with raised bumps), and skin redness (erythema) which occur in a majority of people who are on TALVEY.
Dry Skin (Xerosis): Severe or generalized dry skin is frequent and can affect mucous membranes like the mouth and eyes.
Palmoplantar Peeling / Skin Scaling: Peeling or scaling of the skin, particularly on the palms of the hands and soles of the feet, can develop during treatment with TALVEY.
Nail disorders are also very common when being treated with TALVEY (impacting up to half of patients), including nail fragility, discoloration, ridging, or nails separating and lifting from the nail bed.
Injection Site Reactions of TALVEY include mild redness, swelling, pain, or irritation can happen where the subcutaneous injection is given.
While most skin reactions from TALVEY are mild to moderate and manageable with moisturizers, topical steroids, or dose adjustments, serious skin reactions can occasionally occur.
You should seek medical attention right away if you notice any of the following when being treated with TALVEY.
Blistering, severe peeling, or open sores on the skin.
Rashes accompanied by a fever or flu-like symptoms.
The drug TALVEY is a bispecific antibody that is also known as (talquetamab-tgvs) and is a first in class, T-cell-redirecting bispecific antibody that is also approved by the FDA for the treatment of adults that have heavily pretreated, relapsed or refractory multiple myeloma (a type of blood cancer).
The way that TALVEY works is unlike, traditional monoclonal antibodies, which only target one site, a bispecific antibody like TALVEY, has two distinct "arms" that also bind to tow different proteins simultaneously.
And one arm binds to GPRC5D (which is a protein found in high numbers on the surface of multiple myeloma cells).
And the other arm binds to CD3 (a protein located on the surface of your immune system's T cells).
TALVEY activates your immune system to attack and destroy the cancer cells, by bridging the T cell and myeloma cell together.
Talvey (talquetamab-tgvs) is an immunotherapy, not traditional chemotherapy.
Specifically, Talvey is a bispecific T-cell engager (BiTE) and a type of monoclonal antibody.
It acts like a bridge by attaching to two different proteins at the same time—GPRC5D on multiple myeloma cancer cells and CD3 on your body's immune T-cells.
By bringing them together, Talvey activates your T-cells to find, target, and destroy the cancer cells.
How it differs from chemotherapy: Traditional chemotherapy generally attacks and destroys any fast-growing cells in the body (both cancerous and healthy).
Talvey instead directs your own immune system to specifically recognize and fight the myeloma cells.